This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
San Diego-based Arcturus Therapeutics , a developer of mRNA-based treatments for disease, has signed a deal to receive up to $3M in funding from the Cystic Fibrosis Foundation Therapeutics, a nonprofit which supports drug discovery and development. READ MORE>>.
Pasadena-based venture capital firm Arcturus Capital has scored an exit out of its portfolio this morning, as Milpitas, California-based Pliant Technology was acquired by SanDisk in a deal worth $327M. Arcturus first invested in Pliant in 2007. SanDisk is a major manufacturer of flash memory.
Simi Valley-based Aerovironment said yesterday that it has completed the $405M acquisition of Arcturus UAV, a designer and manufacturer of high performance, unmanned aircraft systems (UAS). The deal had originally been announced on January 13th.
Simi Valley-based unmanned aerial vehicle maker Aerovironment says it is acquiring Arcturus UAV, a developer of unmanned aircraft used by the military, in a deal worth $405M in cash and stock. AeroVironment said it would pay $355M in cash and $50M in stock for Arcturus, which is based in Petaluma, Claifornia.
Augmented reality and holographic technology exist largely as a novelty for most Americans. But as smartphone cameras evolve and 5G networks come online, many investors and businesses are betting that the technology will become commonplace.
Messenger RNA drug developer Arcturus Therapeutics is ready to kick off its first-ever human trials this year, beginning clinical evaluation of its lead drug candidate and testing a vaccine designed to target the novel coronavirus. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.
San Diego-based RNA therapeutics developer Arcturus Therapeutics announced this morning that it is in a strategic collaboration deal, with Johnson & Johnson Innovation. Plus, Janssen will assume responsibility for development and commercialization costs associated with the new program.
San Diego-based Arcturus Therapeutics has received up to $220M in additional financial commitments from the country of Singapore, after receiving positive Phase 1/2 study results on one of its compounds.
Los Angeles-based Arcturus, a developer of 3D video editing tools, said Wednesday afternoon that it has raised $11M in a Series A funding round. The funding was led by Cloudtree Ventures, and also included Autodesk and Epic Games. The startup is led by CEO Kamal Mistry.
Prolacta is venture funded by Alta Ventures, DFJ Frontier, Arcturus Capital, DFJ Mercury, Funk Ventures, Phillip Capital, Gideon Hixon Fund, and Draper Associates L.P. The firm said it will commit a minimum amount of $25,000 annually to fund programs at Komen.
Things have been moving quickly in recent weeks for the San Diego RNA drug developer Arcturus Therapeutics. After initiating a reverse merger last month, Arcturus signed a research collaboration and worldwide licensing agreement with Janssen Pharmaceuticals, part of the Johnson & Johnson (NYSE: JNJ ) family of companies.
San Diego-based Arcturus Therapeutics said today Cystic Fibrosis Foundation Therapeutics has agreed to provide $3 million to fund research and development of a new messenger RNA drug that could be broadly used to treat cystic fibrosis patients. Arcturus says its technology can be used to make.
Prolacta is venture backed by such companies as Health Evolution Partners, Alta Partners, DFJ Frontier, Arcturus Capital, DFJ Mercury, Funk Ventures, Phillip Capital, Gideon Hixon Fund, and Draper Associates. The use of human milk helps avoid serious side effects that can occur with premature infants if they use cow-based milk.
Arcturus Therapeutics (NASDAQ: ARCT ) said today it has fired co-founder and CEO Joseph E. The unexpected announcement nevertheless sent the price of Arcturus shares spiraling in after-hours trading, falling by $1.38, nearly 19 percent, to. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.
The San Diego RNA drug developer Arcturus Therapeutics (NASDAQ: ARCT ) named four new board members Tuesday, after the four directors who fired founding CEO Joseph Payne resigned as part of a settlement agreement that was approved Monday by an Israeli court. No financial terms were disclosed.
TrueCar is venture backed by backed by USAA, Capricorn Investment Group, Upfront Ventures, Anthem Ventures, Vulcan Capital Growth Equity, Peppy Capital Partners, Arcturus Venture Capital, along with others. TrueCar is trading on the NASDAQ Global Select Market as TRUE. READ MORE>>. truecar true buying service scott painter'
The round was led by Prospector Equity Capital and Arcturus Capital, and also included the Pasadena Angels and Tech Coast Angels. Monrovia-based Ondax , a manufacturer of volume holographic grating filters and lasers, said Tuesday that it has officially closed its $2.2M, Series E funding round.
The firm said it has scored Series A funding from Zag, Anthem Venture Partners, Global Retail Partners, Capricorn, Capital One Auto Finance, ARcturus Capital, Scott Painter, and co-founder Tom Taira. According to TrueCar, it will provide information about new car pricing, using the actual price people have paid for cars.
ONDAX is backed by Arcturus Capital, Prospector Equity Capital, and others. Christophe Moser, who is moving to Switzerland to become Professor of Engineering and Industrial Relations at Ecole Polytechnique Federale de Lausanne (EPFL). Moser is a native of Switzerland, and will remain as Chief Technology Officer at the firm.
The schism between Arcturus Therapeutics’ board and its former chief executive is now putting the company at risk of missing key financial reporting deadlines, and possibly even losing its stock listing. Arcturus (NASDAQ: ARCT ) blamed the failure on Joseph Payne, who was fired as CEO on Feb. Arcturus says Payne and others.
In the five years since it was founded, San Diego-based Arcturus Therapeutics (NASDAQ: ARCT ) says it has built a versatile platform for developing a variety of RNA-based medicines. Dueling lawsuits between the ousted CEO and the board could consume. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.
As a showdown stockholders meeting draws near for San Diego’s Arcturus Therapeutics (NASDAQ: ARCT ), a proxy battle is boiling down to an argument over who represents the best interests of shareholders in the tiny RNA drug company. In an April 3 letter addressed to the company’s four board members, Arcturus co-founder and ex-CEO Joseph E.
The San Diego RNA drug developer Arcturus Therapeutics (NASDAQ: ARCT ) on Thursday reinstated fired CEO Joseph Payne and named ResMed (NYSE: RMD ) founder Peter Farrell as chairman of the company’s new board of directors. He co-founded Arcturus and is the company’s largest shareholder, with a 13.7 percent stake.
The firm is venture backed by Anthem Ventures, Arcturus Capital, Capital One, Capricorn Management, and GRP Partners. Painter is best known for being the founder and CEO of CarsDirect.com, but is also heavily involved in local startups such as SharesPost, and other firms through his BrightHouse business incubator.
The board that fired Arcturus Therapeutics co-founder and CEO Joseph E. In a lawsuit filed Tuesday (see below) and in an open letter to shareholders issued Wednesday , the Arcturus (NASDAQ: ARCT ) board says a pattern of alleged misconduct, deceit, and failed leadership by Payne led to his termination on January 25. Payne, who.
Dr. Schuh was previously CEO and Director of AviaraDx, and also served at Arcturus Bioscience and Sequenom. The firm is headed by Antonius Schuh, who serves as founding chairman and CEO; the firm's CFO is Steve Zaniboni.
Zaniboni was also CFO for Arcturus Bioscience and Sequenom, XIFIN noted, adding that Taylor worked at IBM as a strategy executive prior to Acclerys. Most recently, XIFIN said, Zaniboni was CFO of AviaraDx, while Taylor served as vice president of marketing and corporate development for Acclerys Inc.
After postponing a May 7 shareholder vote in a power struggle for control of San Diego’s Arcturus Therapeutics (NASDAQ: ARCT ), the company’s board of directors has set a new date for its showdown with ousted CEO Joseph Payne. In a statement Monday, Arcturus said it has rescheduled its special shareholder meeting for 10 a.m.
TrueCar is venture backed by Zag, Anthem Venture Partners, Global Retail Partners, Capricorn, Capital One Auto Finance, and Arcturus Capital. The new service is free, and is based on automotive transactions within the last four weeks. READ MORE>>.
Zag has previously received venture capital from such firms as Anthem Ventures, GRP Partners, the Tech Coast Angels, Capricorn Management, Capital One, and Arcturus Capital. The firm did not say what drove the growth, and did not provide any financial details on its sales or profitability. READ MORE>>.
The round was led by Rincon Venture Partners, and also included Arcturus Capital and Momentum Venture Management. Long Beach-based Digital Performance, which develops technology for online sales efforts in the after market automotive parts sector, is announcing Monday that it has raised $3.2M in a Series A funding round.
Zag has previously received funding from Anthem Ventures, Arcturus Capital, Capital One, Capricorn Management, GRP Partners, and the Tech Coast Angels. The spokesperson for Zag said that the firm is "not quite ready to make that announcement" and would not releas details until later. READ MORE>>.
Zag is venture backed by Anthem Ventures, Arcturus Capital, Capital One, Capricorn Management, GRP Partners, and the Tech Coast Angels, along with USAA. The spokesperson for Zag said that the firm is "not quite ready to make that announcement" and would not released details until later.
Zag is venture backed by Anthem Venture Partners, USAA, GRP Partners, Arcturus Capital, Callaway Cars and the Skoll Fund. Zag's technology differs from other similar programs in that it offers fully detailed pricing on exact options, rather than just feeding leads into a dealership's fleet or online department. READ MORE>>.
The firm is backed by Anthem Venture Partners, Capital One Auto Finance, GRP Partners, Arcturus Capital, Callaway Cars and the Skoll Fund. Zag develops software used for configuring and pricing new and used automobiles, which it provides on a white-label basis to affinity buying programs. READ MORE>>
Zag is headed by former CarsDirect CEO Scott Painter, and is venture backed by Anthem Venture Partners, Capital One Auto Finance, GRP Partners, Arcturus Capital, Callaway Cars and the Skoll Fund. Zag has now signed up 14 AAA motor clubs, and also provides its technology to Capital One Auto Finance, Overstock.com, and other sites.
The public markets are moving erratically, but Alnylam Pharmaceuticals showed this week that selling equity isn’t the only way for biotech companies to raise cash. Late last year Alnylam (NASDAQ: ALNY ) began exploring potential royalty deals for inclisiran, a drug that uses RNA interference to lower cholesterol.
San Diego-based Arcturus Therapeutics , a developer of RNAi technology, said it has raised $5M in a Series A funding round. According to Arcturus, the funding came from multiple private capital,, high net worth investors from Canada, Japan, and the United States. Names of those capital sources were not announced. READ MORE>>.
As strains of bacteria evolve to fight back against common antibiotics, a slew of biotechnology companies are working to develop ways to combat these “superbugs.” San Diego’s Forge Therapeutics is among those targeting gram-negative bacteria, a type of bacteria that has a protective outer membrane that makes it especially resistant to drugs.
The top biopharma story of the week involves the fast-moving field of lung cancer, which, as we’ve written previously, has several key trials reading out in 2018. A big domino fell this week: data from a two-drug immunotherapy combination developed by Bristol-Myers Squibb. But the results, touted as positive, left more questions than answers.
San Diego-based Arcturus Therapeutics , which is developing RNAi therapeutics to treat disease, said this morning that it has raised $1.3M Arcturus Therapeutics is headed by Joseph E. Arcturus Therapeutics is headed by Joseph E. arcturus therapeutics venture capital rnai lifescience biotech' in a seed fudning round.
If the recent IPO activity seems to be on overdrive, it’s not your imagination. The number of companies filing to go public in the U.S. in the first quarter was up 44 percent compared to the same period a year ago, according to data compiled by consulting and accounting firm EY.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content